In early 2019, NexTec Group took InBios International live on Acumatica, empowering the company with the tools and technology it needs to grow and scale.
About InBios International
InBios International has been on the forefront of infectious disease diagnostic research since 1998. The company was one of the first to market with a Zika diagnostic test and recently developed two COVID-19 tests that have received emergency use authorization from the FDA.
Medical Device Manufacturing
Here’s how NexTec Group and Acumatica helped solve InBios’ challenges.
The company has multiple kit items, which are assembled to order and many of the kits share some of the same components. “It had become nearly impossible to determine if we had enough components to fulfill our orders,” says Bryan Deszell, Manufacturing Manager for
InBios. “Sometimes we’d have five people counting what was on the shelves and matching them to orders to see if we had enough. Now we have that information available in real time.”
With Acumatica, the company has seen a huge improvement in inventory control throughout the supply chain. “We’re able to connect purchase orders to production orders through to sales orders,” explains Deszell. “We trust our numbers. That’s something we didn’t have before.”